1266 completed, 356 recruiting, 322 unknown, 285 terminated. 1632 Phase 2, 559 Phase 1, 415 Phase 3, 100 Not applicable, 76 Phase 4.
Follow this drug Literature Review of Bevacizumab trials Research Report on Bevacizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hematoma Bevacizumab (intra-arterial) - Chronic Subdural Hematoma | Phase 1 | Not yet recruiting | Dheeraj Gandhi | 18 | 2027-01-01 | 2026-07-27 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma NaviFUS System, Lumason, Bevacizumab - GBM | Not applicable | Not yet recruiting | University of Cincinnati | 10 | 2026-12-01 | 2026-06-04 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | Genmab | 602 | 2026-11-01 | 2026-10-05 |
| Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) PRGN-2012, Bevacizumab - Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV) | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 50 | 2026-10-26 | 2026-10-21 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors SYS6043, bevacizumab, carboplatin - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 400 | 2026-10-15 | 2026-09-22 |
| A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal Cancer Serplulimab, Bevacizumab, Oxaliplatin - Locally Advanced Rectal Cancer | Not applicable | Not yet recruiting | Tang-Du Hospital | 48 | 2026-10-15 | 2026-10-13 |
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma Stereotactic Body Radiotherapy, Bevacizumab, Iparomlimab and Tuvonralimab - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 33 | 2026-10-15 | 2026-10-20 |
| Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC FMT combined with QL1706 plus Bevacizumab - Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 20 | 2026-10-10 | 2026-10-08 |
| Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] Mocertatug rezetecan, Bevacizumab - Ovarian Neoplasms | Phase 3 | Not yet recruiting | GlaxoSmithKline | 720 | 2026-10-09 | 2026-10-02 |
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-10-16 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-10-09 |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2026-10-01 | 2026-09-01 |
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
Showing 20 of 2624. Sign in to see all of them.
Colorectal Neoplasms (486) · Carcinoma, Non-Small-Cell Lung (233) · Breast Neoplasms (197) · Ovarian Neoplasms (187) · Glioblastoma (160) · Carcinoma, Hepatocellular (140) · Neoplasms (130) · Rectal Neoplasms (115) · Colonic Neoplasms (111) · Neoplasm Metastasis (108) · Brain Neoplasms (98) · Lung Neoplasms (96) · Fallopian Tube Neoplasms (94) · Carcinoma, Renal Cell (77) · Glioma (70)
National Cancer Institute (NCI) (161) · Hoffmann-La Roche (156) · M.D. Anderson Cancer Center (76) · Genentech, Inc. (54) · Sun Yat-sen University (46) · Fudan University (39) · SCRI Development Innovations, LLC (32) · Memorial Sloan Kettering Cancer Center (31) · Dana-Farber Cancer Institute (28) · Pfizer (23) · Duke University (21) · Massachusetts General Hospital (21) · Alliance for Clinical Trials in Oncology (20) · ImmunityBio, Inc. (18) · AstraZeneca (17)
United States (1213) · China (513) · France (274) · Spain (247) · Italy (205) · Canada (175) · Germany (172) · South Korea (170) · United Kingdom (148) · Australia (139) · Japan (138) · Taiwan (127) · Belgium (110) · Netherlands (109) · Brazil (91)
Annick Desjardins, MD, FRCPC (7) · Norman Wolmark, MD (7) · Hamid Ahmadieh, MD (6) · John Boockvar, MD (6) · John D. Hainsworth, MD (6)
PMID 37185961, PMID 37146227, PMID 32816630, PMID 33067126, PMID 34616010, PMID 17686822, PMID 21941283, PMID 25098701, PMID 32411431, PMID 37260074, PMID 39777725, PMID 41252656, PMID 10628376, PMID 18024865, PMID 18776057, PMID 19064978, PMID 19097774, PMID 19901100, PMID 20573926, PMID 21383283, PMID 21865400, PMID 22204724, PMID 22204725, PMID 23168366, PMID 24138831, PMID 24637997, PMID 25175099, PMID 25218906, PMID 25240821, PMID 25538173, PMID 26884585, PMID 27501767, PMID 27744512, PMID 27986363, PMID 28237539, PMID 29522361, PMID 30059262, PMID 30293873, PMID 30679026, PMID 30957581, PMID 31101691, PMID 31139483, PMID 31268130, PMID 31276981, PMID 31378656, PMID 32164906, PMID 32278676, PMID 32374423, PMID 32427087, PMID 32997907
2023 (29), 2025 (29), 2008 (22), U10CA180868 (21), U10CA027469 (19), 2017 (18), U10CA021115 (17), 2009 (16), 2015 (14), U10CA032102 (14), 2016 (13), 2014 (12), 2018 (12), U10CA031946 (12), U10CA180820 (12)